Showing results (51-60 of 71) with videos related to
Sort By:
Pageof 8
Antimicrobial Agents and Chemotherapy|July 10, 2026
Virologic insights from the phase 3 REDPINE trial: remdesivir in renally impaired and immunocompromised patients with COVID-19Lauren Rodriguez, Kristen Andreatta, Shuguang Chen, et al.AIDS (London, England)|April 25, 2022
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/IPaul E Sax, Kristen Andreatta, Jean-Michel Molina, et al.NPJ Vaccines|November 9, 2023
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeysArchana V Boopathy, Bhawna Sharma, Anurag Nekkalapudi, et al.Microbiology (Reading, England)|May 6, 2025
Oxygen microenvironments in <i>Escherichia coli</i> biofilm nutrient transport channels: insights from complementary sensing approachesBeatrice Bottura, Gail McConnell, Lindsey C Florek, et al.Journal of Viral Hepatitis|June 4, 2026
Genotypes of Hepatitis B and D Viruses Among Patients With Hepatitis D in the United StatesAndrew Lopez, Harish Gopalakrishna, Silvia Chang, et al.Antimicrobial Agents and Chemotherapy|May 9, 2022
Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 VariantsJared Pitts, Jiani Li, Jason K Perry, et al.JHEP Reports : Innovation in Hepatology|March 17, 2022
Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis BNicholas van Buuren, Ricardo Ramirez, Cameron Soulette, et al.Antiviral Research|August 19, 2018
HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland ChinaLai Wei, Masao Omata, Young-Suk Lim, et al.JHEP Reports : Innovation in Hepatology|November 6, 2023
Broad-spectrum activity of bulevirtide against clinical isolates of HDV and recombinant pan-genotypic combinations of HBV/HDVRoberto Mateo, Simin Xu, Alex Shornikov, et al.Proceedings of the National Academy of Sciences of the United States of America|October 8, 2020
Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerasesMichael K Lo, César G Albariño, Jason K Perry, et al.Pageof 8